JP2015534564A - 脱髄障害の治療のための併用療法および使用 - Google Patents

脱髄障害の治療のための併用療法および使用 Download PDF

Info

Publication number
JP2015534564A
JP2015534564A JP2015535889A JP2015535889A JP2015534564A JP 2015534564 A JP2015534564 A JP 2015534564A JP 2015535889 A JP2015535889 A JP 2015535889A JP 2015535889 A JP2015535889 A JP 2015535889A JP 2015534564 A JP2015534564 A JP 2015534564A
Authority
JP
Japan
Prior art keywords
lingo
seq
antibody molecule
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015535889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534564A5 (enExample
Inventor
ディエゴ カデイビッド，
ディエゴ カデイビッド，
シャ ミ，
シャ ミ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2015534564A publication Critical patent/JP2015534564A/ja
Publication of JP2015534564A5 publication Critical patent/JP2015534564A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
    • A61B5/112—Gait analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
    • A61B5/1124—Determining motor skills
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dentistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
JP2015535889A 2012-10-09 2013-10-08 脱髄障害の治療のための併用療法および使用 Withdrawn JP2015534564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261711638P 2012-10-09 2012-10-09
US61/711,638 2012-10-09
PCT/US2013/063873 WO2014058875A2 (en) 2012-10-09 2013-10-08 Combination therapies and uses for treatment of demyelinating disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017247590A Division JP2018044014A (ja) 2012-10-09 2017-12-25 脱髄障害の治療のための併用療法および使用

Publications (2)

Publication Number Publication Date
JP2015534564A true JP2015534564A (ja) 2015-12-03
JP2015534564A5 JP2015534564A5 (enExample) 2016-11-24

Family

ID=49484444

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015535889A Withdrawn JP2015534564A (ja) 2012-10-09 2013-10-08 脱髄障害の治療のための併用療法および使用
JP2017247590A Withdrawn JP2018044014A (ja) 2012-10-09 2017-12-25 脱髄障害の治療のための併用療法および使用
JP2020004952A Withdrawn JP2020055881A (ja) 2012-10-09 2020-01-16 脱髄障害の治療のための併用療法および使用
JP2021176294A Pending JP2022023182A (ja) 2012-10-09 2021-10-28 脱髄障害の治療のための併用療法および使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017247590A Withdrawn JP2018044014A (ja) 2012-10-09 2017-12-25 脱髄障害の治療のための併用療法および使用
JP2020004952A Withdrawn JP2020055881A (ja) 2012-10-09 2020-01-16 脱髄障害の治療のための併用療法および使用
JP2021176294A Pending JP2022023182A (ja) 2012-10-09 2021-10-28 脱髄障害の治療のための併用療法および使用

Country Status (13)

Country Link
US (4) US20150238602A1 (enExample)
EP (2) EP3750560A3 (enExample)
JP (4) JP2015534564A (enExample)
KR (2) KR102257645B1 (enExample)
CN (2) CN109364250A (enExample)
AU (3) AU2013329421A1 (enExample)
BR (1) BR112015007780A2 (enExample)
CA (1) CA2887682A1 (enExample)
EA (1) EA201590709A1 (enExample)
HK (1) HK1213794A1 (enExample)
IL (2) IL238117B (enExample)
MX (2) MX2015004436A (enExample)
WO (1) WO2014058875A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524731A (ja) * 2016-07-13 2019-09-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ−１アンタゴニストの投与計画及び脱髄障害の処置のための使用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
EP3194628A4 (en) * 2014-09-19 2018-02-14 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
HUE057865T2 (hu) 2014-12-11 2022-06-28 Actelion Pharmaceuticals Ltd A poneszimodra, egy szelektív S1P1 receptor agonistára vonatkozó adagolási rend
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
WO2016112270A1 (en) * 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
CA2998183A1 (en) * 2015-09-11 2017-03-16 AbbVie Deutschland GmbH & Co. KG Methods for treating relapsing forms of multiple sclerosis
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
CN110650749A (zh) * 2017-05-15 2020-01-03 肿瘤免疫股份有限公司 使用可溶性cd24进行神经保护和髓鞘再生的方法
US11412968B2 (en) 2017-09-12 2022-08-16 Get Together, Inc System and method for a digital therapeutic delivery of generalized clinician tips (GCT)
SG11202010087UA (en) * 2018-04-13 2020-11-27 Mordechai Chevion Compositions and methods for treatment of demyelination
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CN113584041A (zh) * 2021-04-15 2021-11-02 浙江警察学院 一种转基因斑马鱼(mbp:egfp)脱脊髓疾病模型的构建方法
KR102898110B1 (ko) * 2022-06-13 2025-12-12 고려대학교 산학협력단 키나아제 저해제를 유효성분으로 포함하는 탈수초성 질환 예방 또는 치료용 약학적 조성물
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506603A (ja) * 1993-12-16 1997-06-30 ドクトル レンチュレル アルツナイミッテル ゲーエムベーハー ウント コー 多発性硬化症治療でのペントキシフィリンの使用
JP2005522434A (ja) * 2002-02-06 2005-07-28 アレス トレーディング ソシエテ アノニム 脱髄性疾患における腫瘍壊死因子とインターフェロンの組み合わせ
JP2010515456A (ja) * 2007-01-09 2010-05-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５抗体およびその使用
JP2011225577A (ja) * 2003-01-24 2011-11-10 Elan Pharmaceuticals Inc 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
CA2149326C (en) 1992-11-13 2007-04-17 Mitchell E. Reff Fully impaired consensus kozak sequences for mammalian expression
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
RO120148B1 (ro) 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
AU2002319544B2 (en) 2001-08-10 2008-07-10 Aberdeen University Antigen binding domains from fish
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
WO2003093430A2 (en) 2002-05-03 2003-11-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing sirnas
CN1685063B (zh) 2002-08-12 2011-12-21 新英格兰生物实验室公司 与基因沉默相关的方法和组合物
ZA200505869B (en) * 2003-01-24 2006-11-29 Elan Pharm Inc Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
KR20040086884A (ko) 2003-03-22 2004-10-13 제일모직주식회사 난연성 열가소성 수지 조성물
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2315779A2 (en) * 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
CN106278999B (zh) 2011-02-07 2019-10-25 比奥根Ma公司 S1p调节剂
GB201103526D0 (en) * 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506603A (ja) * 1993-12-16 1997-06-30 ドクトル レンチュレル アルツナイミッテル ゲーエムベーハー ウント コー 多発性硬化症治療でのペントキシフィリンの使用
JP2005522434A (ja) * 2002-02-06 2005-07-28 アレス トレーディング ソシエテ アノニム 脱髄性疾患における腫瘍壊死因子とインターフェロンの組み合わせ
JP2011225577A (ja) * 2003-01-24 2011-11-10 Elan Pharmaceuticals Inc 脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
JP2010515456A (ja) * 2007-01-09 2010-05-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５抗体およびその使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524731A (ja) * 2016-07-13 2019-09-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ−１アンタゴニストの投与計画及び脱髄障害の処置のための使用
JP7149257B2 (ja) 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用

Also Published As

Publication number Publication date
US20200276303A1 (en) 2020-09-03
US20190038744A1 (en) 2019-02-07
KR20150064752A (ko) 2015-06-11
EP3750560A2 (en) 2020-12-16
EA201590709A1 (ru) 2015-09-30
IL269852A (en) 2019-11-28
IL238117A0 (en) 2015-05-31
CN109364250A (zh) 2019-02-22
WO2014058875A2 (en) 2014-04-17
KR102257645B1 (ko) 2021-06-01
IL238117B (en) 2019-10-31
HK1213794A1 (zh) 2016-07-15
MX2015004436A (es) 2015-06-24
JP2018044014A (ja) 2018-03-22
US20150238602A1 (en) 2015-08-27
AU2013329421A1 (en) 2015-04-30
KR20210063443A (ko) 2021-06-01
AU2020203196A1 (en) 2020-06-04
JP2020055881A (ja) 2020-04-09
EP2906240A2 (en) 2015-08-19
IL269852B (en) 2021-08-31
CN104870014A (zh) 2015-08-26
MX2020006431A (es) 2020-09-17
WO2014058875A3 (en) 2014-06-12
JP2022023182A (ja) 2022-02-07
EP3750560A3 (en) 2021-03-24
CA2887682A1 (en) 2014-04-17
AU2018203688A1 (en) 2018-06-14
BR112015007780A2 (pt) 2017-11-28
US20210260185A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
JP2022023182A (ja) 脱髄障害の治療のための併用療法および使用
US20210277111A1 (en) Lingo-1 antagonists and uses for treatment of demyelinating disorders
US20210403556A1 (en) Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders
US20200392229A1 (en) Methods of use of anti-sortilin antibodies
RS55715B1 (sr) Metode lečenja autoimunih bolesti sa dll4 antagonistima
US20240132597A1 (en) Methods of use of anti-sortilin antibodies
CN111789954B (zh) 延缓衰老的方法和药物
HK40040606A (en) Combination therapies and uses for treatment of demyelinating disorders
JP2025118705A (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180308

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180316